Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (2149)	6/8/1999 11:55:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

DG DISPATCH -- EULAR: Celebrex Linked To Fewer GI Ulcers By David Jack Special to DG News GLASGOW, SCOTLAND -- June 7, 1999 -- Professor Gabriele Porro, chairman of gastroenterology, L. Sacco University, Milan, Italy, reviewed the latest safety data on Celebrex™ (celecoxib) at the XIV European League Against Rheumatism (EULAR) Congress being held in Glasgow, Scotland. At clinically effective doses, celecoxib has been shown to inhibit COX-2 without affecting COX-1, Dr. Porro explained. A randomised, double-blind, endoscopic study evaluated the drug's effects on the gastrointestinal tract and on platelet function in patients with osteoarthritis (OA). After 12 weeks of treatment, the rates of gastrointestinal ulcers (confirmed by endoscopy) in the naproxen group (500 mg twice daily) were 16.2 percent. In patients treated with celecoxib, ulcers were found in 3.4 percent of patients treated with 50 mg twice daily, in 3.1 percent of patients taking 100 mg twice daily and in 5.9 percent of patients taking 200 mg twice daily. Ulcers were found in 2.3 percent of patients in the placebo group. The incidence of ulceration in the naproxen group was significantly higher than in the celecoxib groups, although no significant difference was found among the various celecoxib dose groups. Similar differences were found between naproxen and celecoxib in a 12-week trial in patients with rheumatoid arthritis (RA). In both studies, there was no difference between celecoxib and placebo as far as effects on platelet aggregation and bleeding time were concerned. pslgroup.com